Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
129.52
-2.44 (-1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer
May 21, 2021
BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a...
Via
Benzinga
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
May 19, 2021
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)...
Via
Benzinga
Exposures
Product Safety
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
May 08, 2021
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...
Via
Talk Markets
Exposures
COVID-19
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
May 03, 2021
Two of AbbVie's most important assets could get a lot harder to sell.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
A Heavy News Day And Crypto
April 28, 2021
Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today.
Via
Talk Markets
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
April 28, 2021
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against...
Via
Benzinga
Exceptions To A Low Period
April 25, 2021
This past week served as a negative period for my stock holdings, with a couple of exceptions. Here I discuss what those exceptions were and how they moved.
Via
Talk Markets
Currency Manipulation
April 16, 2021
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53.
Via
Talk Markets
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
April 10, 2021
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in...
Via
Talk Markets
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
Heavy News Day - Cheats
April 08, 2021
US job losses were up 744,000 vs a forecast of 694,000.
Via
Talk Markets
BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study
April 08, 2021
BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.